In Section C, contributors will receive ABBV-744 and oral navitoclax. In Phase D, participants will acquire ABBV-744 and ruxolitinib. Contributors will acquire treatment right up until disorder progression or maybe the members are not able to tolerate the study drugs. General, our present-day work highlights the potential utilization of ARV-825 https://joshuam776bny0.wonderkingwiki.com/user